CYP19A1 and breast cancer: The following keywords and combinations were used: “aromatase inhibitors”, “endocrine therapy”, “early breast cancer”, “toxicity”, “adverse effects”, “side effects”, “management”, “fatigue”, “bone loss”, “vasomotor symptoms”, “sexual dysfunction”, “musculoskeletal symptoms”, and “cognitive impairment”.